Albireo Pharma (ALBO) vs. Takeda Pharmaceutical (TKPYY) Head-To-Head Comparison

Albireo Pharma (NASDAQ:ALBO) and Takeda Pharmaceutical (OTCMKTS:TKPYY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.58 per share. Albireo Pharma does not pay a dividend.



Analyst Ratings

This is a summary of current recommendations and price targets for Albireo Pharma and Takeda Pharmaceutical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Albireo Pharma 0 0 5 0 3.00
Takeda Pharmaceutical 0 0 0 0 N/A

Albireo Pharma presently has a consensus target price of $60.33, suggesting a potential upside of 68.06%.

Earnings & Valuation

This table compares Albireo Pharma and Takeda Pharmaceutical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Albireo Pharma $12.74 million 33.93 -$46.11 million ($3.94) -9.11
Takeda Pharmaceutical $15.99 billion 0.00 $1.68 billion N/A N/A

Takeda Pharmaceutical has higher revenue and earnings than Albireo Pharma.

Institutional & Insider Ownership

66.9% of Albireo Pharma shares are owned by institutional investors. Comparatively, 0.2% of Takeda Pharmaceutical shares are owned by institutional investors. 3.7% of Albireo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Albireo Pharma has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Profitability

This table compares Albireo Pharma and Takeda Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Albireo Pharma -2,900.81% -47.03% -32.32%
Takeda Pharmaceutical 7.84% 11.35% 5.57%

Summary

Takeda Pharmaceutical beats Albireo Pharma on 6 of the 10 factors compared between the two stocks.

About Albireo Pharma

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreement with Samsung Bioepis Co., Ltd. to co-develop various biologic therapies; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as drugs for neglected diseases initiative; and Molecular Templates to develop CD38-targeted engineered toxin bodies. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.